陕西中医2024，Vol.45Issue(8)：1048-1051,4.DOI:10.3969/j.issn.1000-7369.2024.08.008
加味麦门冬汤联合安罗替尼治疗晚期驱动基因阴性非小细胞肺癌临床疗效
Clinical efficacy of modified Maimendong decoction combined with anlotinib on advanced driver gene-negative non-small cell lung cancer
摘要
Abstract
Objective:To explore the clinical efficacy of modified Maimendong decoction combined with anlotinib in the treatment of advanced driver gene-negative non-small cell lung cancer(NSLC)of qi and yin deficiency.Methods:The clinical data of patients with advanced driver gene-negative NSLC of qi and yin deficiency type were retrospectively analyzed.They were divided into observation group(n=57)and control group(n=55)according to whether they were treated with Maimendong decoction or not.The clinical efficacy and occurrence of adverse reactions,TCM syn-dromes scores,serum tumor markers[carcinoembryonic antigen(CEA),cytokeratin 19 fragment(CYFRA-21),car-bohydrate antigen 125(CA125)],disease-related biochemical indicators[vascular endothelial growth factor(VEGF),platelet-derived growth factor(PDGF)]and quality of life[Karnofsky Performance Status(KPS)]before treatment and after 3 courses of treatment and survival status after 1 year of treatment were compared between both groups of patients.Results:After 3 courses of treatment,the clinical effective rate and KPS score in observation group were significantly higher than those in control group(all P<0.05),while the levels of serum tumor markers and dis-ease-related biochemical indicators were significantly lower than those in control group(all P<0.05).The survival rate in observation group after 1 year of treatment was higher than that in control group(P<0.05).There were no significant differences in adverse reactions between the two groups(P>0.05).Conclusion:Modified Maimendong de-coction combined with anlotinib can improve the syndrome of qi and yin deficiency of advanced driver gene negative NSLC patients,reduce the level of serum tumor markers,inhibit tumor cell metastasis,improve the quality of life of patients,and have fewer adverse reactions.关键词
肺癌/麦门冬汤/安罗替尼/气阴两虚/晚期/肿瘤标志物Key words
Lung cancer/Maimendong decoction/Anlotinib/Qi and yin deficiency/Advanced/Tumor markers分类
医药卫生引用本文复制引用
王倩,蒋思雨,刘倩希,程帅,袁江,陈璐璐,赵陆轶,何广,刘松江..加味麦门冬汤联合安罗替尼治疗晚期驱动基因阴性非小细胞肺癌临床疗效[J].陕西中医,2024,45(8):1048-1051,4.基金项目
黑龙江省中医药科技项目(GY2022-05) （GY2022-05）
